New services planned to reduce hospital pressures
Dan Leveson, director for places and communities for Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board (ICB), said: "What we really want to do is get all the support in and around people, at home and in their communities, so that we can avoid people going in to the hospital in the first place."With health and social care partners reporting a 20% reduction in the average length of a hospital stay in Oxfordshire, money is now being prioritised to reduce the number of avoidable admissions into hospital.Mr Leveson said: "There is a percentage of people at the moment who are admitted into hospital for non-urgent admissions, that if we had different care, if we had access to hospital at home, district nursing, social care and reablement, then they can stay home."Yearly NHS spending for Oxfordshire is estimated to be between £1.5bn to £2 bn.Plans include to further develop Oxfordshire's single point of access for community services, making it easier to access services like home nursing visits and intermediate care rather than going directly to hospital.The region's urgent community response system will also be expanded to offer an alternative to paramedics taking people to hospital when they can be better cared for at home.Integrated neighbourhood teams will be broadened, with teams specialising in areas including physiotherapy and community nursing being able to provide hospital-level treatment at a more local level, alongside the already established Hospital at Home service.
You can follow BBC Oxfordshire on Facebook, X (Twitter), or Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
29 minutes ago
- Daily Mail
Urgent warning for residents in the Northern Territory as cases of sexually transmitted infection explode
Medical experts are warning residents in the Northern Territory to get tested for syphilis following an explosion in cases of the potentially deadly infection. The NT has recorded more than 183 cases of syphilis so far this year, following back-to-back near-record months since an outbreak began in 2013. Consistently high case numbers prompted the territory's top medical officer to establish a dedicated response team, the syphilis Incident Management Team (IMT) in February. Syphilis can be particularly devastating for pregnant women, leading to miscarriage, stillbirth, neonatal death, low birth weight and congenital syphilis. Australian Medical Association NT president Dr John Zorbas acknowledged the numbers were high, but suggested better testing could be contributing to the spike. 'Sometimes a large increase in case numbers is a good thing,' he told NT News. 'That means we're doing more testing, we're finding these cases and we're actually getting those cases treated.' Of the 183 cases identified in the NT from January 1 to June 22, 93 per cent of cases were successfully treated, a government spokesperson told the publication. Syphilis is a sexually-transmissible infection (STI) usually caused by having vaginal, oral or anal sex with an infected person, through pregnancy and, in rare cases, through skin-to-skin contact. While it is easy to cure if found early, it can cause serious illness, disability and even death if left untreated. The IMT advised pregnant women to test five times across the course of a pregnancy - at the outset, at 28 weeks, at 36 weeks, at birth and six weeks after birth. It also recommended testing for all people aged 15 years and older presenting to any health service including primary health care and emergency departments. Common symptoms include sores or ulcers in the genital areas, anus, cervix or mouth, rash, skin lesions, swollen lymph glands, fever, patchy hair loss, muscle and joint aches, headaches, tiredness and warty lumps. Not all patients will present with symptoms, however, meaning regular testing is crucial to ensure the disease does not cause long-term damage. Syphilis can spread to the nervous system, known as neurosyphilis, which can lead to headaches, altered behaviour, difficulty coordinating muscle movements, paralysis, numbness and even dementia. It can also spread to the eye, known as ocular syphilis, which can cause vision loss, blurred vision, eye pain, eye redness and even permanent blindness. Syphilis was almost entirely eradicated in Australia by the early 2000s but cases have exploded following an outbreak in north-west Queensland in 2011. Since then, the disease has spread nationwide with outbreaks currently active in Queensland, the Northern Territory, Western Australia and South Australia. Case numbers across the country increased 400 per cent between 2011 and 2023, with a disproportionate impact on Indigenous Australian communities. The NT has been hit hardest by the outbreak, with its per capita rate more than five times higher than any other jurisdiction at its peak in 2018. To avoid contracting syphilis, the Department of Health recommends people should get tested regularly and avoid sexual activity while unwell. It also recommends using condoms with condom-safe lubricants during vaginal and anal sex and dental dams during oral sex. You should see your doctor or visit a family planning clinic or sexual health clinic if you are concerned you or anyone you have had sexual contact with has syphilis.
Daily Mail
an hour ago
- Daily Mail
BREAKING NEWS Urgent recall for life-saving device over dangerous defect
An entire line of defibrillators has been urgently recalled after issues with the devices' circuits caused some of them to fail. The federal government issued a notice for medical technology firm Stryker's HeartSine samaritan Public Access Defibrillator (PAD) on June 24. 'A manufacturing problem related to a circuit board component may impair the device's ability to function or cause failure,' it said. 'This failure could occur at any point when the device is holding a charge. This may be in preparation to deliver therapy, while delivering a shock, or after shock delivery. 'The device becomes inoperable after the failure occurs.' The notice said the defect was spotted during quality testing, not patient use. The source of the issue was the Pad-Pak, a single-use battery and electrode cartridge containing the battery to power the defibrillator and two electrode pads. Users should check their AED serial number to see if it is affected, noting the devices are part of a subset of HeartSine samaritan PAD Models 350P, 360P, 450P and 500P. The affected devices are part of a subset of serial numbers beginning with 21, 22, 23 or 24, and are then followed by the letter B, D, E, G or H. Stryker said users should continue monitoring their PAD device to ensure the status indicator is flashing green every five to 10 seconds. They should contact Stryker immediately if the status indicator is flashing red, or they can hear continuous beeping or the voice prompt 'Warning, Low Battery'. Alternatively, they should contact the company if no status indicator is displayed. For further information, Stryker can be reached on 02 9170 9131 or through email at
Rhyl Journal
2 hours ago
- Rhyl Journal
Breast cancer patients ‘denied life-extending drugs because of unfair system'
Breast Cancer Now has demanded 'immediate action' from Health Secretary Wes Streeting, urging him to scrap spending restraints. It is also calling for the NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to lower the bar for what it classes as a very severe health condition. Nice's severity modifier, introduced in 2022, gives treatment for more severe illnesses more weight, meaning the health benefits of certain drugs are valued more highly and more likely to be recommended for NHS use. According to Nice, the process raises the threshold for what it considers to be a cost-effective treatment, meaning it can give more expensive drugs the green light. However, a new report from Breast Cancer Now claims the system means women with incurable breast cancer with months to live may be told their condition does not qualify for the most severe rating. The call comes after it emerged that the life-extending drug Enhertu will not be made available for women with incurable breast cancer on the NHS in England and Wales. In November, Nice said talks with manufacturers AstraZeneca and Daiichi Sankyo over the price of the medication had broken down for the third time with no agreement. Claire Rowney, chief executive at Breast Cancer Now, said: 'The terrifying reality is that unless urgent action is taken thousands of women in the UK with incurable secondary breast cancer could be denied access to vital life-extending treatments because of an unfair system. 'We're talking about patients missing out on access to cutting-edge, effective treatments that could give them more time to be there for special moments such as birthdays or seeing their children or grandchildren start school. 'Treatments, such as Enhertu, that patients in other countries, including Scotland, can access, giving them the chance to live longer. 'Women with secondary breast cancer tell us they feel their lives are being deprioritised by the changes to the system. 'We will not stand by and witness more drugs being rejected or not taken forward, when the devastating cost is thousands more people with secondary breast cancer across England, Wales and Northern Ireland having their lives cut short.' Paula Van Santen, 50, was diagnosed with secondary breast cancer in July 2022, two months after her diagnosis of primary breast cancer. The mother-of-three, from Banbury in Oxfordshire, said: 'Secondary breast cancer has changed the lives of both myself and my family beyond belief. Coming to terms with my diagnosis is the hardest part because I've had to grieve for the life I had, but also the life that I'm not going to have. 'If a new drug can give me another six months, if it gives me another year, it's worth it. 'It could allow me to see my daughter get to 21, see my children get married or meet grandchildren. Just to have a picture with a grandchild so they would know that I existed would be so precious. That's what this could give.' Ms Rowney called for 'change' and said Mr Streeting should scrap 'opportunity-cost neutral' restraints. Opportunity cost neutrality in the Nice severity modifier aims to ensure the new system does not require more or less overall NHS funding than the old one. According to the Breast Cancer Now report, this is 'at the root of the issues with the modifier'. It added: 'It pits end-of-life cancer treatments against other severe conditions like cystic fibrosis in a way that's reductive and unfair to patients. And, ultimately, it creates barriers to the approval of drugs for advanced cancers.' Ms Rowney said: 'The system for deciding whether drugs are approved for use on the NHS must change now. 'We're calling for immediate action from Wes Streeting, Secretary of State for Health and Social Care, to urgently scrap 'opportunity-cost neutral' restraints and for Nice to lower the bar for what it defines as 'a severe condition'. And we stand ready to work with them.' Dr Samantha Roberts, chief executive of Nice, welcomed the report from Breast Cancer Now, saying: 'The independent analysis we commissioned recently showed the new severity weighting is working as intended and expected. 'It is able to be applied more widely – for example to treatments for cystic fibrosis, hepatitis D and Duchenne muscular dystrophy – and has contributed to an increase in positive decisions for cancer medicines and non-cancer medicines. 'And other breast cancer treatments have been recommended since we introduced the severity modifier – including for advanced breast cancer. 'We remain deeply disappointed that we were unable to recommend Enhertu for HER2-low advanced breast cancer. We know this was devastating to all those hoping for a different answer. 'It remains the only breast cancer treatment we have been unable to recommend in seven years.' A Department of Health and Social Care spokesperson said the upcoming 10-year health plan will 'transform the NHS and improve care for those facing cancer'. 'This includes rolling out DIY screening kits for cervical cancer, more radiotherapy machines in every region and opening more Community Diagnostic Centres closer to where people live,' they added. 'We know how disappointing it is to many families that the manufacturers of Enhertu are unwilling to sell this life-extending treatment to the NHS at a fair and reasonable price. Our door remains open to supporting the introduction of medicines at a cost-effective price.'
